Transsexualism and osteoporosis.
The aim of this study was to investigate whether and to what extent our regime of cross-gender hormone replacement therapy might influence osteoporosis development in transsexual patients. We found that after long-term therapy the bone densities of our cross-gender hormone-treated transsexual groups (10 male-to-female and 10 female-to-male) did not show significant differences compared to those of the corresponding biological sex. Moreover, the bone-density during therapy pointed out very little variability and that independent of the gender-alteration (transsexuality-direction) and the age of the transsexuals. Our results indicate that for transsexual patients treated with cross-gender hormone replacement therapy the risk of developing osteoporosis is low.
Schlatterer
K
K
Dept. of Endocrinology, Max Planck Institute of Psychiatry, Munich, Germany.
Auer
D P
DP
Yassouridis
A
A
von Werder
K
K
Stalla
G K
GK
D000328:Adult; D015519:Bone Density / Q000187:drug effects; D005260:Female; D020249:Hormone Replacement Therapy / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000139:chemically induced*; D018570:Risk Assessment; D014189:Transsexualism / Q000150:complications*